


# Training Material for LiiV (Supplier information in VARA)



# Background

- The register VARA was launched in October 2010, in connection with the re-regulation of the Swedish pharmacy market
- The Swedish Government commissioned the Swedish eHealth Agency to take over the task of compiling supplier information, which led to the development of LiiV
- LiiV was launched in November 2016, replacing the Swedish Medical Products Agency's system NPL (National Product Register for Medicinal Products)

# Information flow



# Flow LiiV-VARA

- When the information is saved in LiiV, it is automatically transferred to VARA
- In VARA, the information is quality assured by pharmacists before it is published at midnight
- If any deviation is identified during the quality assurance process, the company will be contacted and requested to update the information in LiiV

All changes must be entered into LiiV by 15:00 (3:00 p.m.) for the information to be published at midnight

Det finns bland annat en handbok som beskriver l


### Ansökan/Application


 [Behörighetsadministratör \(pdf, 38,34 KB\)](#)

 [English: Application user administrator form \(pd](#)

### Vägledning

 [Handbok LiiV \(pdf, 1,22 MB\)](#)

 [English: Handbook LiiV \(pdf, 1,1 MB\)](#)


 [Utbildningsmaterial LiiV \(pdf, 1,39 MB\)](#)

# Handbook LiiV

- The handbook describes pharmaceutical companies' use of LiiV
- [LiiV \(Leverantörernas information i VARA\) - E-hälsomyndigheten](#)

# Log in

- Login via the LiiV information page: [LiiV \(Leverantörernas information i VARA\) - E-hälsomyndigheten](#)
- A personal user account is required
- Logging in requires a username and password



The screenshot shows the LiiV login interface. At the top left is the LiiV logo in purple. To its right is a link that says "Read more about LiiV >". Below this is a light blue box containing the "Log in" heading. Underneath the heading are two input fields: "User name" and "Password". Below the password field is a purple "Log in" button. At the bottom of the light blue box, there is a link that says "If you have forgotten your password, [click here](#)."

# User accounts in LiiV

## *Roles:*

- Read-only – can only view the company's information
- Write access – can edit the company's information
- User administrator – can edit the company's information and create new user accounts linked to the company
- Consultant administrator – can create user accounts for colleagues within the consultancy
- Consultant – is searchable by other companies so that they can grant authorisation to this individual


# Application user administrator

The **first** user at the company submits an application to [servicedesk@ehalsomyndigheten.se](mailto:servicedesk@ehalsomyndigheten.se). This user can then create accounts for colleagues and consultants.

**User information (required fields are marked with \*)**

First name*	Surname*
Company name*	VAT number*
E-mail address for information on user account*	
E-mail address for notification on updates of the company's products	
Telephone number*	Contact person for the eHealth Agency for questions on your company's products* <input type="checkbox"/> YES <input type="checkbox"/> NO
Comments	

# Log in for the first time



**E-hälsomyndigheten**

## You have been given a user account in LiIV

You have been given a user account in LiIV (Leverantörernas information i VARA). Your user name is [redacted].

You must activate your user account yourself in order to log in. Activation takes place in two steps:

1. Request activation link
2. Enter password

[Activate account - Step 1 >](#)


LiIV, administered by the Swedish eHealth Agency, is used for purposes such as prescriptions, medical products, and supplementary information on their use.

[Read more about LiIV >](#)

If you have questions about this mail or about LiIV (Leverantörernas information i VARA), please contact our service desk at [servicedesk@ehalsomyndigheten.se](mailto:servicedesk@ehalsomyndigheten.se) or contact our service desk at +46 771 123456.

Sincerely,  
LiIV Administration, Swedish eHealth Agency

1. An email is sent when the account is created. Click on the link in the email.



## Activate user account in LiIV


Indicate your user name to get an activation link sent to your e-mail address.

User name

I agree to the terms of use for the [redacted]

[Send](#)

2. Enter the user name (from the email). Read and agree to the terms of use.



**E-hälsomyndigheten**

## Activation of user account/password reset in LiIV

You have requested activation of your user account or a password reset in LiIV. Please disregard this e-mail.


Click on the button below to enter a password. The link is valid for 15 minutes.

[Enter password >](#)

If you have questions about this mail or about LiIV (Leverantörernas information i VARA), please contact our service desk at [servicedesk@ehalsomyndigheten.se](mailto:servicedesk@ehalsomyndigheten.se) or contact our service desk at +46 771 123456.

Sincerely,  
LiIV Administration, Swedish eHealth Agency

3. A new email is sent. Click on the link (only valid for 15 minutes).



## Enter password

User name

New password

Confirm new Password

[Save](#)

4. Enter the desired password

# Forgotten password

## Log in

User name

Password

[Log in](#)

If you have forgotten your password, [click here](#).

# General functions

Click here to change language

Click here to change company if you have more than one authorisation

The screenshot shows the Liiv website interface. At the top, there is a navigation bar with the Liiv logo, a search bar, and a user account link. On the right side of the navigation bar, there are two dropdown menus: 'Language: English' and 'Orifarm AB', both with arrows pointing to callout boxes. A 'Log out' link is also present. Below the navigation bar, the main content area features a light blue header for 'Abilify' with a 'Send message' button. Underneath, the product is identified as '10 mg Tablet' with an 'Updated: 2026-03-12 20:11' timestamp and a 'View changelog' link. The main content is organized into two columns of key-value pairs. The left column includes fields like 'Previous trade name', 'On the market', 'Strength numeric with unit', 'Swedish approval number', 'Approval number', 'Marketing authorisation number', 'Approval date', 'Authorisation procedure', and 'Substance description'. The right column includes 'Dose dispensing', 'Dose disp. shelf life', 'Contains lactose', 'Contains latex', 'Biological medicinal product', 'Controlled medicinal product', 'Narcotic class', 'Prescription drug', 'Repeat prescription', 'Additional monitoring', 'Dispensing restriction', 'Dosage unit', and 'Routes of administration'. A tooltip is shown over the question mark icon next to the 'Strength numeric with unit' field, explaining that the field is filled out if strength is indicated in the SPC and cannot be indicated in a single field for combination products. A callout box on the left side of the image points to this question mark icon, stating that it indicates editable fields and that a short description is displayed when the mouse pointer is placed over it.

The question mark indicates editable fields. A short description is displayed when the mouse pointer is placed over the question mark.

Image from a test environment

# Homepage – search for medicines

The screenshot shows the Liiv search interface. At the top, there is a navigation bar with the Liiv logo, a search bar, and user account information (Language: English, Orifarm AB, Log out). The main section is titled "Search for medicines" and contains a search input field, a search button, and an export button. A dropdown menu is open, showing various search parameters, with "Trade name" selected. Below the search area, there is a table titled "Showing all your medicines" with 4339 hits. The table has columns for Trade name, Strength, Product code, Substance, Item number, Sw. approval no., MA number, On the market, and Last modified. Annotations with arrows point to the search input field, the dropdown menu, the table, and the search button.

Enter the desired search term here

Choose search parameter (trade name preselected)

After logging in, a list is displayed showing the medicinal products registered to the company linked to the user account

Click here to go to the product page

Click here to display the product's packages

Trade name	Strength	Product code	Substance	Item number	Sw. approval no.	MA number	On the market	Last modified
Abacavir/Lamivudine Orifarm	600 mg/300 mg				57990		No(0/1)	2025-05-15 16:02
Abacavir/Lamivudine Orifarm	600 mg/300 mg	Film-coated tablet			58456		No(0/1)	2026-04-17 11:27
ABASAGLAR KwikPen	100 enheter/ml	Solution for injection in pre-filled pen				EU/1/14/944	Yes(6/17)	2026-03-12 20:10
Abboticin	1 g	Powder for solution for infusion			63099		No(0/1)	2025-05-15 16:53
	mg/ml					EU/1/04/276	Yes(6/10)	2026-03-12 20:16

Image from a test environment

# Search results

**Search for medicines**

Advagraf Trade name

Exclude withdrawn products  View marketed only  View non marketed only

Search Show all X Export

Filter search results by checking a box

Showing results for ... "A" company's products

Number of hits: 4

Trade name	Strength	Dosage form	Sw. approval no.	MA number	On the market	Last modified
Advagraf	0,5 mg	Prolonged-release capsule, hard		EU/1/07/387	Yes(5/19)	2026-03-12 20:12
Advagraf	1 mg	Prolonged-release capsule, hard		EU/1/07/387	Yes(13/29)	2026-03-12 20:12
Advagraf	3 mg	Prolonged-release capsule, hard		EU/1/07/387	Yes(7/20)	2026-03-12 20:12
Advagraf	5 mg	Prolonged-release capsule, hard		EU/1/07/387	Yes(7/19)	2026-03-12 20:12

Image from a test environment

# Export search results

## Search for medicines

Exclude withdrawn products
  View marketed only
  View non marketed only

Search 🔍
Show all ✕
Export ▼

---

### Showing results for ... "N05"

Number of hits: 248

Trade name ▼
Strength ▼
Dosage form ▼

Abilify	1 mg/ml	Oral solution
Abilify	10 mg	Orodispersible tablet
Abilify	15 mg	Orodispersible tablet
Abilify	10 mg	Tablet
Abilify	15 mg	Tablet
Abilify	30 mg	Tablet
Abilify	5 mg	Tablet

	A	B	C	D
1	Trade name	Strength text	Dosage form	Package content
2	Abilify	1 mg/ml	Oral solution	Flaska, 150 ml (PD: Orifarm AB)
3	Abilify	10 mg	Orodispersible tablet	Blister, 28 x 1 tabletter (PD: Orifarm AB)
4	Abilify	15 mg	Orodispersible tablet	Blister, 28 x 1tabletter (PD: Orifarm AB)
5	Abilify	10 mg	Tablet	Blister, 14 x 1 tabletter (PD: Orifarm AB)
6	Abilify	10 mg	Tablet	Blister, 56 x 1 tabletter (PD: Orifarm AB)
7	Abilify	10 mg	Tablet	Blister, 28 x 1 tabletter (PD: Orifarm AB)
8	Abilify	15 mg	Tablet	Blister, 56 x 1 tabletter (PD: Orifarm AB)
9	Abilify	15 mg	Tablet	Blister, 28 x 1 tabletter (PD: Orifarm AB)
10	Abilify	30 mg	Tablet	Blister, 56 x 1 tabletter (PD: Orifarm AB)
11	Abilify	5 mg	Tablet	Blister, 56 x 1 tabletter (PD: Orifarm AB)
12	Abilify	5 mg	Tablet	Blister, 14 x 1 tabletter (PD: Orifarm AB)
13	Abilify	5 mg	Tablet	Blister, 28 x 1 tabletter (PD: Orifarm AB)
14	ABILIFY MAINTENA	400 mg	Powder and solvent for pr	Injektionsflaska, 3 x (400 mg + 2 ml) (PD: Orifarm AB)
15	ABILIFY MAINTENA	400 mg	Powder and solvent for pr	Injektionsflaska, 400 mg + 2 ml (PD: Orifarm AB)
16	ABILIFY MAINTENA	400 mg	Powder and solvent for pr	Tvåkammarspruta, 1 x (400 mg + 1,6 ml) (PD: Orifarm AB)
17	ABILIFY MAINTENA	720 mg	Prolonged-release suspen	Förfyllid spruta, 1 st (med nålar) (PD: Orifarm AB)
18	ABILIFY MAINTENA	960 mg	Prolonged-release suspen	Förfyllid spruta, 1 st (med nålar) (PD: Orifarm AB)

Image from a test environment

# Display product (1)

## Abilify

10 mg Tablet

Updated: 2024-09-12 21:12 [View changelog →](#)

Previous trade name:		Dose dispensing:	Yes
On the market:	Yes	Dose disp. shelf life:	6 months
? Strength numeric with unit:	10 mg	Contains lactose:	Yes
ATC code:	N05AX12	Contains latex:	No
Product type:	Medicinal product	Biological medicinal product:	
NPL id:	20040607011409	Controlled medicinal product:	No
Swedish approval number:		Narcotic class:	Not classified as a narcotic
Approval number:	182700	Prescription drug:	Prescription only
Marketing authorisation number:	EU/1/04/276	Repeat prescription:	
Approval date:	2004-06-04	Additional monitoring:	No
Authorisation procedure:	Centralised procedure	Dispensing restriction:	
Substance description:	Aripiprazol	? Dosage unit:	tablett
		Routes of administration:	Oral use

---

Interchangeability

Substance group	Pharmaceutical form group	Strength group
Aripiprazol	Tablett	10 mg

Click here to edit information about the product

Edit

Send message

Click here to display the changelog

# Display product (2)

**Pharmaceutical product 1:**  
*Amounts given per basic pharmaceutical unit*

Ingredient role	Substance	Quantity	Unit	Additional	CAS no.
Active ingredient	alfakalcidol	0,5	microgram	The amount given is the target amount	41294-56-8
Excipient	allurarött AC aluminiumlack				68583-95-9
Excipient	butylhydroxianisol				25013-16-5
Excipient	butylhydroxitoluen				128-37-0
Excipient	glycerol				56-81-5
Excipient	sorbitol				50-70-4

## Packaging

<u>Package content</u> ▼	Item number	Product code	NPL pack id	Prescription status ▼	On the market ▼	Organisation ▼	
<b>Blister, 100 kapslar</b>	104259	07046261042598	20101013100856	Yes	Yes	Orifarm Generics AB	<a href="#">Edit</a>
<b>Blister, 100 × 1 kapslar (endos)</b>					No	Orifarm Generics AB	<a href="#">Edit</a>
<b>Blister, 98 kapslar</b>					No	Orifarm Generics AB	<a href="#">Edit</a>
<b>Blister, 98 × 1 kapslar (endos)</b>					No	Orifarm Generics AB	<a href="#">Edit</a>

**Organisations:**  
Marketing Authorisation Holder:  
**Orifarm Generics A/S, Energivej 15, POB 69, DK-5260 Odense S, Denmark (DK25674030)**

Local representative:  
**Orifarm Generics AB, Box 56048, Ingmar Bergmans Gata 2, 102 17, Stockholm, Sweden (SE556622893701)**

Click on the desired row in order to display the package

Click here to edit the package directly

# Edit product

## Alfacalcidol Orifarm

**0,5 mikrogram Capsule, soft** Updated: 2016-10-14 22:47  
Orifarm Generics AB (SE556622893701)  
NPL id: 20100612000147

? Strength numeric:       ? Unit:

[Save](#) [Cancel](#)

Kapsel      0,5 mikrog

Enter the desired information and click "Save"

## Trade name®

[Edit](#) [Send message](#)

Value for 'Strength numeric with unit' is missing

In the event of a validation error, correct the information and save again

# Withdrawn product

### Search for medicines

A10 ATC code

Exclude withdrawn products  View marketed only  View non marketed only

[Search](#) [Show all](#) [Export](#)

---

Showing results for ... "A10"

Number of hits: 7

Trade name	Strength	Dosage form
Glimepirid Copyfarm	1 mg	Tablet
Glimepirid Copyfarm	2 mg	Tablet
Glimepirid Copyfarm	3 mg	Tablet
Glimepirid Copyfarm	4 mg	Tablet
Metformin Orifarm	1000 mg	Film-coated tablet
Metformin Orifarm	500 mg	Film-coated tablet

Withdrawn products and packages are greyed out in lists and displayed with a red stripe on the product/package page

## Glimepirid Sandoz

[Edit](#) [Send message](#)

Withdrawal date: 2018-11-19

### 3 mg Tablet

Updated: 2024-05-30 14:25 [View changelog](#)

Previous trade name:	No	Dose dispensing:	Yes
On the market:	No	Dose disp. shelf life:	6 months
Strength numeric with unit:	3 mg	Contains lactose:	Yes
ATC code:	A10BB12	Contains latex:	No
Product type:	Medicinal product	Biological medicinal product:	No
NPL id:	20050701000032	Controlled medicinal product:	No
Swedish approval number:	22657	Narcotic class:	Not classified as a narcotic
Approval number:	226570	Prescription drug:	Prescription only
Marketing authorisation number:		Repeat prescription:	
Approval date:	2005-12-09	Additional monitoring:	No
Authorisation procedure:	Mutual recognition procedure	Dispensing restriction:	
Substance description:		Dosage unit:	
		Routes of administration:	

# Changelog

Atacand				
<a href="#">← View product</a>				
<b>16 mg Tablet</b> Orifarm AB NPL id: 20060704000052				
Changelog				
Changed ▲	Field ▼	Previous value	New value	Changed by ▼
2016-10-31 09:03	Strength numeric unit		mg	anna.andersson
2016-10-31 09:03	Strength numeric		16	anna.andersson

The changelog shows changes made by the Swedish eHealth Agency, pharmaceutical companies and the MPA. A changelog is also available on the package page.

# Display package

**Burk, 100 kapslar** [← View product](#) [Edit](#) [Send message](#)

**Alfacalcidol Strides**  
0,5 mikrogram Capsule, soft  
Strides Nordic ApS (DK40533605)  
NPL pack id: 20191213100114

Updated: 2025-03-13 21:22 [View changelog →](#)

[?](#) Mult 2 X [?](#) Mult 1 X [?](#) Quantity and unit 100 capsule(s)

[?](#) Container: Jar Prescription status: Yes

<a href="#">?</a> For dose dispensing only:	No	<a href="#">?</a> Item number:	598328
<a href="#">?</a> For hospital use only:	No	<a href="#">?</a> Previous item number:	
<a href="#">?</a> Contains latex:	No	<a href="#">?</a> Product code:	05031676002222
<a href="#">?</a> Safety features:	Yes	<a href="#">?</a> Previous product code:	

[?](#) On the market: Yes [?](#) Reason:

[?](#) On the market date: [?](#) Consent to publication of reason:

[?](#) No longer on the market from: [?](#) Forecast for when the package will be available again:

[?](#) Marketing ceases: [?](#) Supplementary information to the Swedish Medical Products Agency:

Click here to change information about the package

Click here to display the changelog

# Edit package

## Burk, 100 kapslar

**Alfacalcidol Strides**  
0,5 mikrogram Capsule, soft  
Strides Nordic ApS (DK40533605)  
NPL pack id: 20191213100114

Updated: 2025-03-13 21:22

<input type="text" value=""/>	<input type="text" value=""/>	<input type="text" value="100"/>	<input type="text" value="capsule(s)"/>
<input type="text" value="Jar"/>	<input type="text" value="No"/>	<input type="text" value="05031676002222"/>	
<input type="text" value="598328"/>	<input type="text" value="No"/>	<input type="text" value="No"/>	

The Swedish Medical Products Agency will be notified of any changes in the marketing status. The information may be made available to the general public. The Handbook contains detailed information about what is sent to the Swedish Medical Products Agency. Please note that notifications regarding shortages should not be made in LiIV.

E-service for reporting medicine shortages to Swedish Medical Products Agency

Only the fields that can be changed are displayed. Enter the desired information and click "Save".

# Important to know

- All information that the Swedish Medical Products Agency sends to LiiV is passed directly on to VARA and FASS.
- A reference guide for defining “on the market” can be found in the LiiV handbook, section 7.
- Information about a product is passed on to pharmacy operators and healthcare stakeholders when the company sets the first package of the product to “on the market” = yes in LiiV.

# Email when updates are made by the Swedish Medical Products Agency

When a change is made to any product or package owned by the company, an email is sent to those who have provided an email address for notifications

## Update available in Liiv

To Liiv users at Medartuum AB

The Swedish Medical Products Agency has updated the following information in Liiv as of 2016-10-31:

Trade name	Strength	Drug form	NPL id/Npl pack id	Attribute that has been changed	Previous value	New value
Abilify	15 mg	Tablet	Npl pack id: 20051130100140	Package content	Blister, 56 x 1 tabletter (PD: Medartuum AB)	Blister, 86 x 1 tabletter (PD: Medartuum AB)

This e-mail message is sent for informational purposes when the Medical Products Agency has made a change in Liiv to any of the products your company is responsible for.

[Read more about Liiv >](#)

If you have questions about this mail or about Liiv (Leverantörernas information i VARA), please send an e-mail to [serviceesk@ehalsomyndigheten.se](mailto:serviceesk@ehalsomyndigheten.se) or contact our service desk at +46 771-76 62 00.

Sincerely,

Liiv Administration Swedish eHealth Agency

# Send message

The image shows a sequence of steps for sending a message from a product page. The first step is clicking the 'Send message' button on the product page. The second step is choosing a recipient in the 'Send message' dialog box. The third step is the email composition interface, where the recipient and subject are pre-filled.

**1. Click here**

**2. Choose recipient**

**3. An email is created with certain information pre-filled**

**Artelac**  
Eye drops, solution in single-dose container  
Updated: 2016-10-07 21:14 [View changelog →](#)

**Send message**

For questions regarding the information in Liiv please contact the organisation responsible for the information. See handbook for more information.

**Information owner:**  
the Medical Products Agency: [nplcentral@lakemedelsverket.se](mailto:nplcentral@lakemedelsverket.se)  
the Dental and Pharmaceutical Benefits Agency (TLV): [registrator@tlv.se](mailto:registrator@tlv.se)  
the Swedish eHealth Agency: [servicedesk@ehalsomyndigheten.se](mailto:servicedesk@ehalsomyndigheten.se)

Cancel

Skicka Outlook  
Från...  
Till... [servicedesk@ehalsomyndigheten.se](mailto:servicedesk@ehalsomyndigheten.se)  
Kopia...  
Ämne: Accupro® Comp 19930629000083 - Question regarding information in Liiv

# My user account

Liiv Search for medicines **My user account** Language: English Orifarm AB Log out

## My user account

User name:  
**test.test**

First name:  
Test

Last name:  
Test

Language:  
English

E-mail:  
test@test.se

Telephone:  
11111111

Selected login:  
Orifarm AB

### Authorisation

Organisation: SE556548762501 - Orifarm AB	Authorisation role: Write access	E-mail for notifications: test@test.se	Valid until: -	Contact person for questions: Yes
--	-------------------------------------	---	-------------------	--------------------------------------

Save

On this page you can update the information about your user account

Email address used for communication regarding your user account, including password recovery

Email address for information about updates in Liiv (can be left empty)

Image from a test environment

# Administration

This page is only available for users with the roles **user administrator** and **consultant administrator**

Liiv | Search for medicines | My user account | Administration | Language: English | Orifarm Generics AB | Log out

## Administer authorisations

Orifarm Generics AB (SE556622893701)

Assign authorisation to consultant | Create new user account

Name	E-mail, user account	Authorisation	E-mail for notifications	Contact person	Consultant
Test Test	test@test.se	User administrator	test@test.se	Yes	Yes

Provide authorisation to a consultant here

Create an account for a colleague here

A list of the company's users is displayed here (in this case, Orifarm AB)

*Image from a test environment*

# Create user accounts

## Create new user account

First name:

Last name:

Language:

E-mail:

Telephone:

### Authorisations for Orifarm AB (SE556548762501)

Authorisation role:

E-mail for notifications:

Valid until:

Contact person for questions:

Enter the email address used for information about the user account. An email will be sent to this address when the user account is created.

Choose the language for emails and the user interface

Choose the role for the user

Email address for notifications about updates in LiiV (optional)

Choose a date if the account is to be temporary. **This is not a mandatory field.**

Select whether the person is to be a contact person for the Swedish eHealth Agency

# User account created

**Administer user account** ← Administer authorisations

Changed by: test.test ✓ Updated: 2026-05-04 09:11

User name: **test.testtest2** Last logged in:

Status: **Inactive**

First name:  E-mail:  ←

Last name:  Telephone:

Language:

✓ An e-mail message with information about activating the account has been sent to vara@ehalsomyndigheten.se

**Authorisations for Orifarm Generics AB (SE556622893701)**

Authorisation role:  E-mail for notifications:  Valid until:   Contact person for questions:

An email has been sent to this email address

Image from a test environment

# Assigning authorisation to consultants (1)

**Administer authorisations**

Orifarm Generics AB (SE556622893701)

Name	E-mail, user account	Authorisation	E-mail for notifications	Contact person	Consultant
Test TestTest	testtesttest@test.test	Write access	testtesttest@test.test	Yes	No
Test Test	test@test.se				

1. Click Assign authorisation to a consultant

**Assign authorisation to consultant**

Orifarm Generics AB (SE556622893701)

Select consultant organisation:

Select organisation

2. Search for the consultancy company to be engaged

**Assign authorisation to consultant**

Orifarm Generics AB (SE556622893701)

Select consultant organisation:


Test konsult AB

User with consultant organisation Test konsult AB

Name	E-mail, user account	Authorisations for Orifarm Generics AB
Test Test	test@test.se	User administrator

3. Select the consultant to be engaged

# Assigning authorisation to consultants (2)

 | LiiV    Search for medicines    My user account    Administration    Language: English    Orifarm Generics AB    Log out

## Edit authorisations for consultant

← Administer authorisations    Updated: 2026-04-22 14:14


Consultant organisation:  
**Test konsult AB**

First name:     E-mail:

Last name:     Telephone:

Language:

### Authorisations for Orifarm Generics AB (SE556622893701)

Authorisation role:     E-mail for notifications:     Valid until:      Contact person for questions:

The consultant is already registered in LiiV (under the consultancy company).

The only information that can be entered here is the authorisation for the company itself.

*Image from a test environment*

# Questions?

[servicedesk@ehalsomyndigheten.se](mailto:servicedesk@ehalsomyndigheten.se)

Tel. +46 771-76 62 00



**E-hälsomyndigheten**  
Swedish eHealth Agency